Trending...
- SacraPod Suites Unveils AI-Powered 'Work + Rest' Smart Hospitality Model for Retrofitting Underused Motels Across the U.S
- From Real Estate to Reel Power: H.L Woods Carves His Legacy as a Cutting-Edge Visionary Filmmaker
- Airwavz Solutions Appoints Monte Dube to Market Advisory Board to Strengthen Healthcare Wireless Strategy
HemoSphere Alta™ Advanced Monitoring Platform with Predictive, Smart Algorithms Helps Clinicians Proactively Address Instability in Blood Flow and Pressure in Critical Situations
FRANKLIN LAKES, N.J., April 21, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has launched a new advanced hemodynamic monitoring platform with predictive, artificial intelligence (AI) based algorithms that can help clinicians proactively address blood pressure instability and optimize blood flow to help avoid potential life-threatening situations during procedures.
HemoSphere Alta™ platform is the company's most advanced hemodynamic monitoring technology available and is the first major product launch from the Advanced Patient Monitoring business since its acquisition by BD. The new product advances BD's leadership in smart, connected care technologies that use clinical data and AI to help clinicians improve patient outcomes and optimize clinical workflows.
One of the key innovations is the new Cerebral Autoregulation Index (CAI), a first-of-its-kind parameter that indicates whether the brain is likely to maintain stable blood flow despite changes in blood pressure and offers personalized insights into a patient's blood pressure requirements. Clinicians can access CAI when using a noninvasive ForeSight IQ™ Sensor, placed on the patient's forehead, combined with an Acumen IQ ™ Sensor, connected to the patient's arterial line. The HemoSphere Alta™ platform also includes the Acumen Hypotension Prediction Index (HPI)™ software that predicts when a patient could have a low blood pressure event, which has been demonstrated to reduce the depth, duration and severity of hypotension in several large multicenter studies.
"Research over the past two decades has demonstrated the wide variability of the lower limit of cerebral blood flow autoregulation between individuals, as well as the risk for patient morbidity and mortality when blood pressure is maintained below this threshold," said Dr. Charles Hogue, chairman of the Department of Anesthesiology at Northwestern University Feinberg School of Medicine in Chicago. "The availability of the novel Cerebral Autoregulation Index provides clinicians with a tool to detect conditions of impaired autoregulation and can help identify a patient's lower limit of autoregulation. This, in combination with Hypotension Prediction Index technology and other advanced software and algorithms on the HemoSphere Alta™ platform allows us to both customize and predict patients' low blood pressure."
More on illi News
The new monitor also features an improved design to streamline the user experience, including a larger 15" high-resolution, customizable touchscreen display, split-screen views and is designed to minimize disruptive pop-ups. Voice and gesture command features help maintain sterility and allow for hands-free interaction with the monitor, such as silencing alarms and switching views. These improvements offer a more intuitive and efficient interface.
"HemoSphere Alta™ marks the latest milestone in our continuum of connected care innovations by redefining the clinician experience with more efficient workflows and increased usability," said Tim Patz, president of BD Advanced Patient Monitoring. "These AI-driven enhancements of advanced algorithms and machine learning provide clinicians with more insights and clinical decision support to help improve the quality of care for their patients."
With the recent acquisition of Advanced Patient Monitoring, BD continues to advance its collaboration with clinicians to develop advanced patient monitoring solutions that help improve the quality of care for patients around the world. For more information about HemoSphere Alta™, visit bd.com/HemoSphereAlta.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
More on illi News
SOURCE BD (Becton, Dickinson and Company)
FRANKLIN LAKES, N.J., April 21, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has launched a new advanced hemodynamic monitoring platform with predictive, artificial intelligence (AI) based algorithms that can help clinicians proactively address blood pressure instability and optimize blood flow to help avoid potential life-threatening situations during procedures.
HemoSphere Alta™ platform is the company's most advanced hemodynamic monitoring technology available and is the first major product launch from the Advanced Patient Monitoring business since its acquisition by BD. The new product advances BD's leadership in smart, connected care technologies that use clinical data and AI to help clinicians improve patient outcomes and optimize clinical workflows.
One of the key innovations is the new Cerebral Autoregulation Index (CAI), a first-of-its-kind parameter that indicates whether the brain is likely to maintain stable blood flow despite changes in blood pressure and offers personalized insights into a patient's blood pressure requirements. Clinicians can access CAI when using a noninvasive ForeSight IQ™ Sensor, placed on the patient's forehead, combined with an Acumen IQ ™ Sensor, connected to the patient's arterial line. The HemoSphere Alta™ platform also includes the Acumen Hypotension Prediction Index (HPI)™ software that predicts when a patient could have a low blood pressure event, which has been demonstrated to reduce the depth, duration and severity of hypotension in several large multicenter studies.
"Research over the past two decades has demonstrated the wide variability of the lower limit of cerebral blood flow autoregulation between individuals, as well as the risk for patient morbidity and mortality when blood pressure is maintained below this threshold," said Dr. Charles Hogue, chairman of the Department of Anesthesiology at Northwestern University Feinberg School of Medicine in Chicago. "The availability of the novel Cerebral Autoregulation Index provides clinicians with a tool to detect conditions of impaired autoregulation and can help identify a patient's lower limit of autoregulation. This, in combination with Hypotension Prediction Index technology and other advanced software and algorithms on the HemoSphere Alta™ platform allows us to both customize and predict patients' low blood pressure."
More on illi News
- READY FOR NEW BUILDS – Pond & Waterfall Construction Season Starts Now!
- Generic Trade Marks 15 Years of Leveling the Trading Field for all Futures Traders
- HeyGears Achieves Breakthrough in Multi-Material Resin 3D Printing, Overcoming Bottlenecks in Dental Manufacturing
- Levata Acquires Logiscenter to Accelerate Growth in Enterprise IT and Data Capture Solutions
- Smart Resnse Unveils Smart Resnse(SRMS) Token-Powered AI Orchestration Platform to Revolutionize Multi-Billion Dollar Market
The new monitor also features an improved design to streamline the user experience, including a larger 15" high-resolution, customizable touchscreen display, split-screen views and is designed to minimize disruptive pop-ups. Voice and gesture command features help maintain sterility and allow for hands-free interaction with the monitor, such as silencing alarms and switching views. These improvements offer a more intuitive and efficient interface.
"HemoSphere Alta™ marks the latest milestone in our continuum of connected care innovations by redefining the clinician experience with more efficient workflows and increased usability," said Tim Patz, president of BD Advanced Patient Monitoring. "These AI-driven enhancements of advanced algorithms and machine learning provide clinicians with more insights and clinical decision support to help improve the quality of care for their patients."
With the recent acquisition of Advanced Patient Monitoring, BD continues to advance its collaboration with clinicians to develop advanced patient monitoring solutions that help improve the quality of care for patients around the world. For more information about HemoSphere Alta™, visit bd.com/HemoSphereAlta.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
More on illi News
- Josh and Heidi Follow Up the Much Anticipated and Successful Launch of the "Spreading the Good BUZZ" Podcast with a Personal Request
- Startup Born of CTE + Depression Launches Japandi Supply House
- Revolutionary Blockchain Platform Okh Finance Announces Okh Finance(OKKH) Token Launch to Transform Global Asset Leasing Market
- Cover Girl Finalist Teisha Mechetti Questions Legitimacy of Inked Originals Competition, Demands Transparency
- Sylver's Debut Book Reveals Massive Industry Oversight
Contacts: | |
Media: | Investors: |
Troy Kirkpatrick | Adam Reiffe |
VP, Public Relations | Sr. Director, Investor Relations |
858.617.2361 | 201.847.6927 |
[email protected] | [email protected] |
SOURCE BD (Becton, Dickinson and Company)
Filed Under: Business
0 Comments
Latest on illi News
- Dr. John Salerno of Salerno Wellness Introduces Their New Full Body Capsule for Advanced LED Light Therapy Patient Treatments
- Digi 995 Expands Its Universe: All Three Novels Now Available in Paperback Worldwide
- Chicago: Mayor Brandon Johnson on Track to Hit Summer Youth Employment Goal with Almost 29,000 Young People Hired for Third Consecutive Year of Expanded Opportunities
- $14M Expansion Deal with Famed David Lloyd Highlights Rebrand of Sports, Entertainment and Gaming Innovation by AI Driven, Online Fan Engagement Co
- Heartfelt Dreams Foundation Launches Campaign to Build CHD Hospital
- Radarsign Tackles Intersection Safety with Launch of Grid-Free Solar LED Stop Sign
- Miami Real Estate Agent Drastically Increases Interest In Homes
- Adostics & Genmega Announce the Introduction of A-POD
- LIB and Nidec Rejoin Forces for Giant TH-0098 Temperature Humidity Test Chamber
- Digi 995 Audiobooks Officially Released: Fans Can Now Listen to the Complete Trilogy
- Naperville: Two Men Charged with Aggravated Street Racing
- Heritage at South Brunswick Offers Immediate Townhome Appointments and Special Mortgage Incentive Fast-Moving Sales
- NASA Collaborative Agreement for Supply of Thin-Film Solar Tech for Orbital Application to Advance Development of Thin-Film PV Power Beaming: $ASTI
- Exciting New Era of Sports, Entertainment & Gaming Innovation Spotlighted by Rebrand of Expanding AI Driven, Online Fan Engagement Company: SEGG Media
- Service Ninjas Debuts First-of-Its-Kind "Membership" Platform for Home Service Pros
- BIYA Forecasts 2025 Surge with ¥300M ($41.8 M USD) in Revenue and ¥25M Profit from Cloud Based HR Solutions: Baiya Intl. Group (N A S D A Q: BIYA)
- Paul E. Saperstein Co. Announces Geographic Expansion of Auction Services
- Celebrate National Beef Tallow Day with South Chicago Packing
- Florida Broker Bent Danholm Featured in the Daily Mail's U.S. Real Estate Coverage
- Robin Launches Legal Intelligence Platform to solve intelligence gap in Fortune 500 legal teams